Unknown OBSERVATIONAL NCT05525065

Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs)

Investigating the Nature and Prevalence of Glucocorticoid-related Morbidity in Patients With Autoimmune Bullous Disease (AIBD) Using the Glucocorticoid Toxicity Index (GTI)

Sponsor: Premier Specialists, Australia

Conditions Autoimmune Bullous Dermatosis Glucocorticoids Toxicity

Interventions GlucoCorticoid

Updated 5 times since 2022 Last updated: Aug 28, 2023 Started: Feb 2, 2019 Primary completion: Sep 1, 2023 Completion: Sep 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Autoimmune Bullous Dermatosis and Glucocorticoids Toxicity, this trial is ongoing. The trial is conducted by Premier Specialists, Australia and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Unknown

Status: Active Not Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Active Not Recruiting
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting
Sep 2023 — Jul 2024 [monthly]

Active Not Recruiting
Sep 2022 — Sep 2023 [monthly]

Active Not Recruiting

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Premier Specialists, Australia
Steritas

Data source: Premier Specialists, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia